Latest Administration News

Whitefield Industrials Limited has confirmed a fully franked ordinary dividend of AUD 0.105 per share for the half-year ending September 2025, alongside setting the Dividend Reinvestment Plan and Bonus Security Plan issue price at AUD 5.39.

Bioxyne Limited has secured a pioneering manufacturing and supply agreement to enter the emerging medicinal cannabis markets of Costa Rica and Panama, positioning itself as a first mover with promising revenue potential.

Jameson Resources has raised an extra A$450,000 through a discounted share placement, reinforcing investor confidence in its Crown Mountain coal project amid ongoing regulatory progress.

Neurizon Therapeutics has secured FDA clearance for its lead drug candidate NUZ-001 to enter the HEALEY ALS Platform Trial, marking a key regulatory milestone and setting the stage for patient enrollment in early 2026.

Lindian Resources has awarded all major non-process infrastructure contracts for its Kangankunde Rare Earths Project in Malawi, marking a pivotal step toward first production in late 2026. Construction is underway with strong schedule confidence and capital discipline.

Charger Metals NL has announced a $0.02 per share call on its partly paid shares to raise up to $854,175, supporting ongoing lithium exploration at its Lake Johnston project. The company also updates on its maiden lithium resource and upcoming drilling plans.

Vulcan Steel Limited has explained the late filing of a director’s interest notice due to an administrative error and outlined steps to strengthen compliance. The company commits to enhanced reminders and board training to prevent future delays.

Dome Gold Mines Ltd is launching a $7 million convertible note offering aimed at funding key developments in its Fiji mining projects, including the Sigatoka feasibility study and exploration programs.

LTR Pharma has received regulatory clearance from the Therapeutic Goods Administration to commence its Phase II clinical trial of SPONTAN, focusing on men aged 65 and over. Patient recruitment is set to begin early next year, aiming to address a key gap in erectile dysfunction treatment.

Immuron Limited reports topline results from a Uniformed Services University trial of a third-party ETEC product that missed its primary endpoint, reaffirming commitment to its established Travelan dosing ahead of FDA discussions.

Lotus Resources plans a significant share consolidation to better align its capital structure with its ASX300 status, aiming to attract a broader investor base. The move, subject to shareholder approval, coincides with a proposed update to the company’s constitution.

Jatcorp Limited has announced a fully underwritten pro-rata rights issue to raise approximately $4.2 million, aiming to strengthen working capital and accelerate growth in China and Southeast Asia. Eligible shareholders can subscribe at $0.15 per share with an option for additional shares under a Top-Up Facility.